尊龙网址登录官网

Be the most trusted biotech company

2025-03-26

First Japanese Patient Dosed in Phase 3 MRCT of Dual HER2 Blockade Therapy for HER2+ GC
2025-03-25

Henlius Announces China’s NMPA Approval of Phase 2 Clinical Trial for HLX79 Plus HANLIKANG in Active Glomerulonephritis
2025-03-24

Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY
2025-03-19

Henlius Receives Orphan-Drug Designation for HLX22(Innovative anti-HER2 mAb) in the U.S. for Gastric Cancer
2025-03-05

Henlius Successfully Holds First In-Person Investigator Meeting in Japan, Accelerating Global Clinical Research for Innovative Pipeline
2025-02-26

Updated Long-term Survival Results from the International Multicenter Phase 3 Clinical Trial of HANQUYOU Published in The Breast
2025-02-19

Henlius Bevacizumab Secures First Overseas Approval, Accelerating Henlius' Expansion into Latin American Market
2025-02-18

Clinical and Translational Science Publishes Phase 1 Clinical Results of Henlius’ HLX14
2025-02-12

Phase 3 MRCT Results of Denosumab Biosimilar HLX14 Released at ORS 2025

1
2
3
4